This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Time to share my women’s health updates from February 2024: research breakthroughs, clinical trial findings, endometriosis deep dive, and more. Meanwhile, innovations like Hera Biotech’s non-invasive test and Ziwig Biotech’s saliva test offer hope for a quicker diagnosis.
With this acquisition, Gerresheimer strengthens its European footprint with additional production sites and underpins its market position as a leading full-service provider and global partner for the pharma and biotech industries. The closing was preceded by the fulfillment of customary closing conditions. EBITDA margin and Adj.
Innovative startups in the health IT, medical device, and biotech fields were among the shining stars at the annual Collision conference. The 2024 conference was held in Toronto, ON for the final time. These companies stood out with their pragmatic, resourceful, and nimble approach to solving healthcare challenges.
Whether they are digital health, medical device, biotech, or pharma companies, healthtech has costly and inefficient sales processes that often stem from a lack of foundational data & insights to reach the right target markets efficiently and effectively. Originally announced February 5th, 2024
Voloch, formerly co-founder at Immunai, an AI-driven cancer immunotherapy company valued at over $1 billion, brings deep AI and biotech experience alongside Jacobstein (ex-Guardant Health, Immunai) and Sud (ex-Ribbon Health, Palantir Technologies). Originally announced November 19th, 2024 For more information, visit jiminihealth.com.
Biotech Showcase is true to its name – great companies are highlighted.” Tina Elder, Global Managing Director, EBD Group US, said, “Biotech Showcase has once again shown itself to be the premiere destination for innovators and partners to access a powerful network of industry decision-makers, media and top investors.
As we kick off 2024, we wanted to start the new year with a series of 2024 Health IT predictions. There is a growing interest in the integration of safety services with technology, and this will continue into 2024. In fact, we got so many that we had to narrow them down to just the best and most interesting.
MDisrupt was founded by Gadelrab, a seasoned health tech executive who has successfully commercialized healthcare and life sciences, served on the executive team at 23andMe, and advised many leading companies in the biotech and genetics sectors. Originally announced October 15th, 2024 MDisrupt has raised $6.6
Doximitys fiscal Q3 2025 results, ending December 31, 2024, underscore this momentum: revenue climbed 25% year-over-year to $168.6 While giants like UnitedHealth or biotech stars like Vertex Pharmaceuticals often dominate headlines, Doximitys niche focus and execution have propelled it ahead. million and $565.6 free cash flow margin.
Read more… This Week’s Health IT Jobs for August 28, 2024: Many roles looking for Epic expertise, along with listings seeking experienced engineers. Biotech software vendor Seqera acquired tinybio , maker of a ChatGPT tool for medical researchers.
The round was led by Eventide Asset Management (Eventide), which invests in biotech and life science healthcare companies seeking solutions for unmet clinical needs. Originally announced August 21st, 2024 million in Series B funding, bringing its total funding to date to $31.5
–(BUSINESS WIRE)– #Biotech –Taking a people-first approach, BioscienceLA, the ecosystem accelerator for life sciences in Greater Los Angeles, has launched its inaugural Leadership Catalyst Program for trailblazers in biotechnology and related sectors.
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients.
Pathology Watch : An end-to-end dermatopathology software platform, including AI interpretation; acquired by Sonic Healthcare in January 2024 for $150 million. Debut Biotech : A leading cell-free biomanufacturing company that launched its own skin care product line in 2023 and raised a $20 million Series B led by L’Oreal.
The JP Morgan 42nd Annual Healthcare Conference will take place January 8-11, 2024 in San Francisco, CA, USA. This unparalleled gathering of healthcare and biotech leaders showcases the enduring power of collaboration and innovation, shaping the future of healthcare. What is the JP Morgan Healthcare Conference?
ADT Biotech 7.5 Mesa Biotech (Thermo Fisher) 7.42 Mesa Biotech (Thermo Fisher) 7.42 Announces Two Acquisitions 6.36 Nigerian Govt Approves Alere HIV Self-Test Kit 6.37 Boots launches UTI test and treatment service across 37 branches 6.38 Scanwell Health moves beyond home UTI testing 6.39 Tasso scores $6.1M 1DropDiagnostics 7.2
Big Pharmas looming patent cliffs could drive outlier deals (7-8x or more) for late-stage innovators, especially in biotech-adjacent HealthTech. Post-2024 U.S. Smaller, unprofitable startups may see compression (3-4x) unless they prove profitability or secure strategic buyers. This is down from 6.5x 1x for compliant firms (e.g.,
Unlearn partners with pharma sponsors, biotech companies, and academic institutions to streamline and optimize clinical trials, enabling researchers to assess the safety and efficacy of new treatments more quickly and accurately. Originally announced February 8th, 2024 For more information, please visit unlearn.ai
–(BUSINESS WIRE)– One Mind , a leading mental health non-profit based in Napa Valley, CA, today announced the 2024 cohort of its flagship One Mind Accelerator program. From digital health to biotech, from Pre-Seed to Series B, and from first-time founders to serial entrepreneurs, this cohort is indeed eclectic.
Combined, the network helps pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, and solve unique geographic and market-specific challenges.
A New Era for AI-Enabled Bioinformatics The biotech and bioinformatics landscape is rapidly evolving, driven in part by technological advances in AI. About Seqera Seqera is the driving force behind Nextflow, MultiQC, and the Seqera Platform – the modern biotech stack. Originally announced August 6th, 2024 Stay tuned!
The broader economic slowdown and high-interest rates have impacted the tech sector in general, and digital health companies haven't been immune Future Outlook:While there haven't been significant numbers of digital health IPOs in 2023 and 2024 so far, some analysts view this as a temporary slowdown. In a form filed with the U.S.
The facility’s location will further EIT’s current partnerships in the Oxford biotech and technology communities, expand collaborations with the University of Oxford, and support the new Ellison Scholars programme. Prof Bell will also become Co-CEO of EIT Global, alongside Dr David Agus.
Optum and Uber are partnering to make non-urgent medical transportation and healthy food delivery covered benefits for certain Medicare Advantage plans beginning in 2024. RedHealthy Communications : PR and marketing for biotech, life sciences, and digital health.
The broader economic slowdown and high-interest rates have impacted the tech sector in general, and digital health companies haven't been immune Future Outlook: While there haven't been significant numbers of digital health IPOs in 2023 and 2024 so far, some analysts view this as a temporary slowdown. In a form filed with the U.S.
Digital health is expected to be a $379bn market by 2024, with truly global and society-shaping potential. “[The As a result, more and more investors are paying attention to the health sector which, due to its complexity, has traditionally been left to biotech or medical devices investors.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content